Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-7: axicabtagene ciloleucel versus standard of care for relapsed/refractory diffuse large B-cell lymphoma
MOH_2018-08-07_002200Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Apr 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, transformed (t-FL) comparing Axicabtagene ciloleucel with Standard of care (2 arms). Started Apr 2018; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on MOH_2018-08-07_002200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-07_002200.